A Phase 3 interventional study of Timolol and Tafluprost and Fixed Dose Combination of tafluprost and timolol in Ocular Hypertension and Open-angle Glaucoma, sponsored by Santen Oy. Completed at 1 site in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-08.
Sponsored by Santen Oy (part of Santen Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. — 1 open to participants now, 2 under way, 1 of them phase 3. Glaucoma, Open-Angle · Santen Pharmaceutical Co., Ltd..
Among the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 7 that started in 2011, is one of 17 in phase 3, and was the 10th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. is open now, in 8 countries. Recruiting first, the newest first:
Santen SAS · Sites in Austria, Belgium, Germany and 5 more countries
Ages 18–85
By country, each count listing its studies:
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 18 · Phase 4 1
First in 2005; this study’s year is marked. 7 started in 2011.
This study's enrollment of 401 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 165 across the 31 interventional studies, 196 across the 4 observational. Of the 33 that completed or were terminated, 14 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Santen Oy, one of the names counted as Santen Pharmaceutical Co., Ltd.. Under that name alone:
Santen Oy is the lead sponsor of 8 studies on the registry; none are open to participants now.
1 of the studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07235592Santen SASPRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost and timolol (FDC) to concomitant administration of tafluprost and timolol.
This study will enroll patients who have ocular hypertension or glaucoma.
The study schedule includes seven visits to the study site and three stages:
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
This study's enrollment of 401 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Santen Oy is the lead sponsor of 8 studies on the registry; none are open to participants now.
Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Concomitant administration of preservative-free timolol and tafluprost eye drops
Drug: Timolol and Tafluprost
Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops
Drug: Fixed Dose Combination of tafluprost and timolol
Drug pages: Timolol · Tafluprost
Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily Treatment period 6 months
Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily. For masking purposes also: vehicle for timolol administered twice daily Treatment period 6 months
Change from baseline in the average diurnal intra-ocular pressure (IOP) at 6 months
Time frame: 6 months
Change from baseline in average diurnal IOP at 2 weeks, 6 weeks and 3 months
Time frame: 2 weeks, 6 weeks and 3 months
Change from baseline in timewise IOPs
Change from baseline in timewise IOPs (at 8:00, 10:00, 16:00) at 2 weeks, 6 weeks, 3 months and 6 months
Time frame: 2 weeks, 6 weeks, 3 months and 6 months
The record gives a start of Mar 2011, a primary completion of Apr 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.